A Setmelanotide-like Effect at MC4R Is Achieved by MC4R Dimer Separation

Melanocortin 4 receptor (MC4R) is part of the leptin-melanocortin pathway and plays an essential role in mediating energy homeostasis. Mutations in the MC4R are the most frequent monogenic cause for obesity. Due to increasing numbers of people with excess body weight, the MC4R has become a target of interest in the search of treatment options. We have previously reported that the MC4R forms homodimers, affecting receptor G(s) signaling properties. Recent studies introducing setmelanotide, a novel synthetic MC4R agonist, suggest a predominant role of the G(q/11) pathway regarding weight regulation. In this study, we analyzed effects of inhibiting homodimerization on G(q/11) signaling using previously reported MC4R/CB1R chimeras. NanoBRET(TM) studies to determine protein-protein interaction were conducted, confirming decreased homodimerization capacities of chimeric receptors in HEK293 cells. G(q/11) signaling of chimeric receptors was analyzed using luciferase-based reporter gene (NFAT) assays. Results demonstrate an improvement of alpha-MSH-induced NFAT signaling of chimeras, reaching the level of setmelanotide signaling at wild-type MC4R (MC4R-WT). In summary, our study shows that inhibiting homodimerization has a setmelanotide-like effect on G(q/11) signaling, with chimeric receptors presenting increased potency compared to MC4R-WT. These findings indicate the potential of inhibiting MC4R homodimerization as a therapeutic target to treat obesity.

Automated summary

In this study, the effects of inhibiting homodimerization on G(q/11) signaling were analyzed using chimeric receptors. The results show that inhibiting homodimerization has a setmelanotide-like effect on G(q/11) signaling, with chimeric receptors presenting increased potency compared to wild-type MC4R. These findings indicate the potential of inhibiting MC4R homodimerization as a therapeutic target to treat obesity.